1. The composition of the immunomodulator, and the composition of the immunomodulator includes: a. cationic liposome delivery vehicle； and b. a nucleic acid molecule for treating respiratory disease in cattle. 2. The composition according to claim 1, wherein the liposome delivery vehicle comprises lipids selected from multilayer vesicular lipids and extrusion lipids. The composition according to claim 2, wherein the liposome delivery vehicle comprises lipid pairs selected from the group consisting of DTMA and cholesterol； DOTAP and cholesterol； DOTIM and cholesterol, and DDAB and cholesterol. 4. The composition according to claim 3, wherein the nucleic acid molecule is an isolated nucleic vector of bacterial origin without a gene insert, or a fragment thereof. The composition according to claim 4, for an administration method selected from the group consisting of intravenous, intramuscular, intradermal, intraperitoneal, subcutaneous, spray / aerosol, oral, intraocular, intratracheal and intranasal. 6. The composition according to claim 5, in which the biological agent is selected from the group comprising immunostimulatory proteins, immunogens, vaccines, antimicrobial agents, or any combination thereof. A composition according to claim 1, wherein the cattle respiratory disease is caused by a viral infection and / or bacterial infection. The composition according to claim 7 for reducing clinical signs caused by Mannheimia haemolytica in livestock, comprising an immunomodulator composition, wherein the immunomodulator composition includes: a. lipid combination of DOTIM and cholesterol； and, b. a nucleic acid molecule that is an isolated nucleic vector of bacterial origin without1. Композиция иммуномодулятора, причем композиция иммуномодулятора включает:a. катионное липосомное средство доставки； иb. молекулу нуклеиновой кислоты для лечения респираторного заболевания у крупного рогатого скота.2. Композиция согласно п.1, в которой липосомное средство доставки включает ли
